CONTINUE TO SITE ➞

Don't miss tomorrow's biopharma industry news

Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.

Daily Dive M-F

Commercialization Weekly Every Wednesday

Gene Therapy Weekly Every Thursday

Emerging Biotech Weekly Every Tuesday

By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Deep Dive
Library
Events
Press Releases

Pharma
Biotech
FDA
Clinical Trials
Deals
Drug Pricing
Gene Therapy

What We're Reading: Page 248

Industry reads hand-picked by our editors

Dec 13, 2018

TIME
The Little-Known Way Pharma Companies Hook People On Their Costly Drugs
Bloomberg
A Harvard Professor Made $400 Million in Moderna’s Biotech IPO
BioCentury
Government shutdown could hobble FDA

Dec 12, 2018

The New York Times
Seeking Clues to Longevity in Lonesome George’s Genes
The Wall Street Journal
Scientists Skeptical About Gene-Edited Baby Experiment
STAT
Lawmaker chastises Pfizer for reverting to price hikes next month

Dec 11, 2018

The New York Times
How to Cut U.S. Drug Prices: Experts Weigh In
STAT
The military pushed it. The FDA went along. Is the newest opioid any better?
Evaluate
Macrogenics’ safety scare could be contagious
Quartz
The most screwed-up employee perk in America (and the man who just might fix it)

Dec 10, 2018

The Washington Post
Generic drug price-fixing investigation expands to 300 drugs and 16 companies
The New York Times
What These Medical Journals Don't Reveal: Top Doctors' Ties to Industry
Evaluate
Death of a unicorn
STAT
Ethical, scientific issues plagued paper from 'CRISPR babies' team

Dec 07, 2018

Pitchbook
Moderna hits $7.6B in upsized debut
FiercePharma
Actelion inks $360M deal to resolve DOJ kickbacks probe
Reuters
Sanofi plans 670 job cuts in France by end 2020
Stat
Democrats are eyeing a valuable pharma asset: its patents

Dec 06, 2018

Nature
How to respond to CRISPR babies
CNN
HHS contradicts reports on fetal tissue research contract
Time
An inside look at Apple's biggest step yet in health care

Dec 05, 2018

Bloomberg
The Opioid Epidemic’s First Corporate Casualty May Be a Drugmaker That Helped Fuel the Crisis
STAT
4 big questions ahead of Moderna's public debut — biotech's biggest ever
Reuters
Bayer halts vilaprisan drug trials due to toxicology data

Previous Next

Get the free newsletter

Subscribe to BioPharma Dive for top news, trends & analysis

Email:

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

A valid email address is required. Please select at least one newsletter.

Library resources

Trendline
Inside the world of cell therapies Supported by ProBio CDMO
Trendline
Inside the market strategies of today’s drugmakers Supported by Evaluate
Trendline
The latest developments on the gene therapy frontier Supported by Mirus Bio LLC

View all

Company Announcements

View all | Post a press release

Events

View all | Promote an event

Industry Intel

Top Ways that AI Will Change Life Sciences Webinar - on demand • Provided by Salesforce
AI-Powered Biomarker Discovery: From Screening to Translational Insights Webinar - on demand • Provided by Danaher
2026 Life Sciences AI & Data Predictions Webinar - on demand • Provided by Snowflake

Explore

About
Editorial Team
Contact Us
Newsletter
Purchase Licensing Rights
Press Releases
What We're Reading

Reach our audience

Advertising
Post a press release
Promote an event

Related Publications

Healthcare Dive
MedTech Dive

Industry Dive is an Informa TechTarget business.

This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 02466.

Home
- Pharma
- Biotech
- FDA
- Clinical Trials
- Deals
- Drug Pricing
- Gene Therapy
Deep Dive
Library
Events
Press Releases

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Email:

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

A valid email address is required. Please select at least one newsletter.